Wockhardt Limited
WOCKPHARMA
Peringkat dalam Saham
#4503
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Harga Saham
$21.02
Kapitalisasi Pasar
$3.42B
Perubahan (1 hari)
-2.48%
Perubahan (1 tahun)
37.78%
Negara
IN
Perdagangan Wockhardt Limited (WOCKPHARMA)
Kategori
Healthcare
Margin Operasi untuk Wockhardt Limited (WOCKPHARMA)
Margin Operasi per October 2026 TTM: 13.78%
Menurut laporan keuangan dan harga saham terbaru dari Wockhardt Limited, margin operasi saat ini (TTM) adalah 13.78%. Pada akhir 2024, margin operasi perusahaan adalah 29.55%.
Riwayat margin operasi untuk Wockhardt Limited dari 2004 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Mengubah |
|---|---|---|
| 2026 (TTM) | 13.78% | -60.31% |
| 2025 | 34.72% | 17.50% |
| 2024 | 29.55% | -555.32% |
| 2023 | -6.49% | -769.07% |
| 2022 | 0.97% | -108.37% |
| 2021 | -11.59% | 252.28% |
| 2020 | -3.29% | 338.67% |
| 2019 | -0.75% | -85.60% |
| 2018 | -5.21% | 70.26% |
| 2017 | -3.06% | -136.34% |
| 2016 | 8.42% | -44.64% |
| 2015 | 15.21% | -12.54% |
| 2014 | 17.39% | -50.41% |
| 2013 | 35.07% | 21.64% |
| 2012 | 28.83% | 33.84% |
| 2011 | 21.54% | 37.64% |
| 2010 | 15.65% | -23.62% |
| 2008 | 20.49% | -4.87% |
| 2007 | 21.54% | -3,091.67% |
| 2006 | -0.72% | -136.36% |
| 2005 | 1.98% | -89.48% |
| 2004 | 18.82% | 0.00% |
Margin Operasi untuk perusahaan sejenis atau pesaing
| Perusahaan | Margin Operasi | Perbedaan Margin Operasi | Negara |
|---|---|---|---|
| 62.34% | -95.48% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 0.77% | -99.94% |
US
|
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.